Latest filings (excl ownership)
EFFECT
Notice of effectiveness
30 Apr 24
424B2
Prospectus for primary offering
29 Apr 24
424B2
Prospectus for primary offering
29 Apr 24
DEF 14A
Definitive proxy
25 Apr 24
S-3
Shelf registration
10 Apr 24
8-K
Other Events
26 Mar 24
8-K
Departure of Directors or Certain Officers
14 Mar 24
10-K
2023 FY
Annual report
13 Mar 24
8-K
Results of Operations and Financial Condition
13 Mar 24
D
$50.96 mm in equity / options, sold $50.96 mm, 4 investors
7 Mar 24
8-K
Regulation FD Disclosure
5 Mar 24
8-K
Entry into a Material Definitive Agreement
28 Feb 24
424B5
Prospectus supplement for primary offering
28 Feb 24
8-K
Proceeds to fully fund first Phase 3 study of cadisegliatin, expected to initiate in mid-2024
28 Feb 24
8-K
Termination of a Material Definitive Agreement
22 Dec 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
19 Dec 23
8-K
Other Events
12 Dec 23
8-K
Other Events
20 Nov 23
8-K
Other Events
15 Nov 23
8-K
Regulation FD Disclosure
15 Nov 23
10-Q
2023 Q3
Quarterly report
9 Nov 23
8-K
Financial Statements and Exhibits
9 Nov 23
8-K
Entry into a Material Definitive Agreement
1 Nov 23
DEF 14C
Information statement
25 Sep 23
PRE 14C
Preliminary information
15 Sep 23
10-Q
2023 Q2
Quarterly report
11 Aug 23
8-K
Results of Operations and Financial Condition
11 Aug 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
20 Jul 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
26 Jun 23
8-K
Submission of Matters to a Vote of Security Holders
8 Jun 23
10-Q
2023 Q1
Quarterly report
11 May 23
8-K
Results of Operations and Financial Condition
11 May 23
DEF 14A
Definitive proxy
26 Apr 23
10-K
2022 FY
Annual report
6 Mar 23
8-K
Results of Operations and Financial Condition
6 Mar 23
8-K
Other Events
1 Feb 23
8-K
Regulation FD Disclosure
6 Jan 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
23 Dec 22
8-K
Departure of Directors or Certain Officers
13 Dec 22
10-Q
2022 Q3
Quarterly report
10 Nov 22
Latest ownership filings
SC 13D/A
MacAndrews & Forbes Inc.
22 Mar 24
3
Anne M. Phillips
14 Mar 24
4
JULIAN BAKER
7 Mar 24
3
JULIAN BAKER
7 Mar 24
3
Raymond Cheong
7 Mar 24
SC 13D
Samsara BioCapital, L.P.
5 Mar 24
SC 13D
BAKER BROS. ADVISORS LP
5 Mar 24
3
Initial statement of insider ownership
29 Feb 24
4
SRINIVAS AKKARAJU
29 Feb 24
3
SRINIVAS AKKARAJU
29 Feb 24
4/A
Jonathan Isaacsohn
21 Jun 23
4
JOHN A FRY
21 Jun 23
4
Fahed Al-Marzooqi
21 Jun 23
4
Chandresh Harjivan
21 Jun 23
4
Keith R. Harris
21 Jun 23
4
Howard L. Weiner
21 Jun 23
4
HERSH KOZLOV
21 Jun 23
3
Barry K. Brown
6 Mar 23
4
Steven L. Tuch
13 Dec 22
3
Steven L. Tuch
13 Dec 22
4
JOHN A FRY
30 Nov 22
SC 13G
Medpace Investors, LLC
23 Aug 22
4
Jonathan Isaacsohn
18 Aug 22
3
Jonathan Isaacsohn
18 Aug 22
4
Keith R. Harris
17 Aug 22
3
Keith R. Harris
17 Aug 22
3
PAUL J SEKHRI
8 Aug 22
4
Fahed Al-Marzooqi
15 Jul 22
4
Howard L. Weiner
6 Jul 22
4
HERSH KOZLOV
6 Jul 22
4
Chandresh Harjivan
6 Jul 22
4
JOHN A FRY
6 Jul 22
3
Tahnoon Bin Zayed S. Al-Nahyan
23 Jun 22
3
Fahed Al-Marzooqi
10 Jun 22
SC 13D
G42 Investments AI Holdings RSC Ltd.
10 Jun 22
3
Chandresh Harjivan
10 Jun 22
SC 13D/A
MacAndrews & Forbes Inc.
1 Jun 22
4
Rich S. Nelson
4 Mar 22
4
RONALD O PERELMAN
21 Dec 21
SC 13D/A
MacAndrews & Forbes Inc.
12 Nov 21